Levation Pharma

Company Overview

Snapshot

Founded in September 2017 by Houman David Hemmati, Levation Pharma operates with 1–10 employees. The company has raised $1.93 million across one funding round from two investors, including lead investor Peregrine Ventures. In February 2023, Levation Pharma initiated a Phase I/II clinical trial for LEV-102, its treatment for Acquired Blepharoptosis.

Business overview

Levation Pharma is an Israeli-American company focused on developing treatments for Acquired Blepharoptosis, a condition characterized by drooping upper eyelids, often associated with aging. The company's core product, LEV-102, is a proprietary odorless, colorless, and rapidly drying aqueous gel designed for topical application to the upper eyelids. This product, which uses oxymetazoline as its active pharmaceutical ingredient, aims to stimulate Mueller’s muscle to lift the upper lid, functioning similarly to an eyeshadow primer. Levation Pharma operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals and Drugs Discovery & Development, targeting the healthcare, life sciences, and cosmetics markets.

Strategic signal

In February 2023, Levation Pharma initiated a Phase I/II clinical trial for its lead product, LEV-102, targeting. This advancement signals the company's progression from preclinical development to human trials, a critical validation step for its topical oxymetazoline gel. For investors, this move indicates significant de-risking and potential for future clinical and commercial milestones in the ophthalmology and cosmetic treatment markets.

Company Intelligence Q&A

What is Levation Pharma's primary product?

Levation Pharma's primary product is LEV-102, a proprietary topical aqueous gel containing oxymetazoline, designed to treat Acquired Blepharoptosis by lifting drooping upper eyelids.

When did Levation Pharma initiate its clinical trial for LEV-102?

Levation Pharma initiated a Phase I/II clinical trial for LEV-102, its treatment for Acquired Blepharoptosis, in February 2023.

Who are the founders of Levation Pharma?

Levation Pharma was co-founded by Houman David Hemmati MD, PhD.

What is the total capital raised by Levation Pharma?

Levation Pharma has raised a total of $1.93 million across one funding round.

Which investors participated in Levation Pharma's funding round?

Levation Pharma received funding from Peregrine Ventures and Pontifax in June 2022.